Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.
ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.
YOY related to the Core Business
SaaS GROSS MARGINS
94% Renewal Rate
^ YOY denotes Year-over-Year change in metric.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCViii that are yet to be reported as recognised revenue.
iii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.
All FY’22 revenue and cash flow numbers are unaudited.
ARR, CRP and TCV are unaudited, non-AASB financial metrics that do not represent revenue in accordance with Australian Accounting Standards. The values shown for total ARR and CRP across all lines of business, including the Core Business and Clinical Business.
All figures are stated in Australian dollars (AUD) unless otherwise notated.
ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.
To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:
Locked Bag A14
NSW 1235, Australia
Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:
ImpediMed maintains an active communications program with investors and the market.
ImpediMed’s share register is managed by Link Market Services Limited.
ImpediMed is focused on reducing our carbon footprint whilst providing you with timely corporate updates and disclosures.
Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options for how ImpediMed shareholders receive communications. ImpediMed will no longer send physical meeting documents unless a shareholder requests a copy to be mailed.
Electronic communication has the added advantage of being timelier and more cost effective, which benefits all shareholders, and ImpediMed encourages all shareholders to provide an email address so we can communicate with you electronically when shareholder notices become available online, for items such as meeting documents, dividend statements and annual reports.
Shareholders can still elect to receive some or all of their communications in physical or electronic form. To review your communication preference, or sign up to receive your shareholder communications via email, please update your details at the Link Investor Centre https://investorcentre.linkmarketservices.com.au/Login/Login.
If you are a Shareholder and require an additional copy of a communication, need further information about the options available to you or have questions about your holding, visit the Link Investor Centre https://www.linkmarketservices.com.au/ or contact the Registry:
Shareholders can use the Link Investor Centre at https://investorcentre.linkmarketservices.com.au/Login/Login to:
To view your shareholding Link Investor Centre, visit: https://investorcentre.linkmarketservices.com.au/Login/Login.